lottery chances of winning
No. 16 Cincinnati tests efficient offense vs. Alabama State
Although home security cameras may seem like the perfect gift for a friend or family member, there are a few problems I've found over the years in regards to gifting them. First, I don't want to give someone an indoor cam if what they really need is an outdoor version. Second, I usually want to keep my gift budget low, especially for more casual friends and family. And third, I don't want to give a gift that comes with baggage like lots of features locked behind a subscription fee. The TP-Link Tapo C120 cam , now on sale for an amazing $25 for Black Friday , is the perfect answer to all of these concerns. On its own, this Tapo cam is no slouch. In my tests, I found the 2K resolution very useful (1080p is so last year for home cams). Plus, it comes with all of the important smart features, like two-way audio, smart alerts with object recognition, color night vision, motion detection and more. It's basically an all-in-one security device. But it's the extra features that really make it perfect for a holiday purchase. Here's where the Tapo C120 shines and why it's such an ideal gift. You also may want to stop by our complete Black Friday guide and our list of the top cheap home security cameras (which includes another one of my Tapo favorites). Hey, did you know? CNET Deals texts are free, easy and save you money I can give the Tapo C120 cam as a gift without knowing all the details The Tapo C120 cam has two-way audio. The more I dug into the C120, the more I realized it was the perfect cam gift. First, you don't have to sign up for a subscription fee to get any important services. Everything important is on the cam for free, and it supports local video storage. However, I would advise adding a cheap microSD card to the cam so the recipient doesn't have to buy one. Tapo cams are famous for their affordability and this cam is currently available for under $30, an amazing price for a do-everything smart home camera. Even at its full price of $40, it's still an awesome bargain for what it does. I've never seen such a complete and trustworthy cam for such a budget price before, so you can save plenty of your holiday gift budget. In my tests I found this cam lives up to its indoor/outdoor claims. It comes with plenty of weather resistance that worked well even in my high desert conditions. You can place it indoors and move it later, so you don't have to worry about where your recipient wants to use it. Is the Tapo C120 cam on sale for Black Friday? Yes! It's currently on sale for nearly 40% off at $25, and I fully expect that deal to extend through the Black Friday weekend. That being said, supplies may not extend that long so if you want to give a security camera as a gift, I suggest you act a bit sooner rather than later. Remember, if one spot like Amazon runs out of stock, it may be available in other places, like TP-Link's own website . If you're looking for additional affordable gifts, check out our latest Black Friday deals , including phone deals and our new shopping tricks for 2024 sales .IPO Frenzy next week: Five main-board, six SMEs to hit primary market to raise Rs 18,500 crore PTI Updated: December 8th, 2024, 17:30 IST in Business , Sci-Tech 0 Pic- IANS Share on Facebook Share on Twitter Share on WhatsApp Share on Linkedin New Delhi: The IPO market is set to be bustling next week, with 11 companies like Vishal Mega Mart, TPG Capital-backed Sai Life Sciences and fintech firm One Mobikwik Systems gearing up to launch their initial share sales, collectively aiming to raise nearly Rs 18,500 crore. Other mainboard IPOs to be launched during this period are Inventurus Knowledge Solutions Ltd and Blackstone-owned diamond grading firm International Gemmological Institute (India) Ltd. Also Read Mcap of 6 of top-10 most valued firms jump Rs 2 lakh crore; TCS, HDFC Bank lead gainers 2 hours ago FPIs return to Indian equities with Rs 24,454 crore inflow in December first week 3 hours ago Alongside the five main-board IPOs, six SMEs are preparing to float their maiden public issues next week to garner over Rs 150 crore collectively. Together, these 11 companies aim to raise approximately Rs 18,500 crore through public offerings. These IPOs will span various sectors and deal sizes and include fresh issues and offers for sale. The companies are tapping the primary market to provide an exit route to the existing shareholders, raise funds for expansion plans, retire debt and support working capital requirements. Trivesh D, COO of Tradejini, an online brokerage house, had said the Maharashtra election verdict and the UP Lok Sabha by-election results created a positive market sentiment that could boost IPO activity and fundraising efforts. While 2024 has been a strong year for IPOs overall, some recent issues have struggled in the secondary market, highlighting the recurring challenge of pricing during a bull run when issuers often aim for higher valuations, he stated. So far in 2024, 78 main-board companies, including Hyundai Motor India, Swiggy, NTPC Green Energy, Bajaj Housing Finance and Ola Electric Mobility, have mobilised around Rs 1.4 lakh crore collectively via mainboard. This was way higher than Rs 49,436 crore garnered by 57 firms through the route in 2023. The IPOs of Vishal Mega Mart, Sai Life Sciences and Mobikwik will be open for public subscription on December 11 and conclude on December 13. Further, the three-day initial share-sales of Inventurus Knowledge Solutions and International Gemmological Institute will open on December 12 and December 13, respectively. Before this, the public issues of Property Share Investment Trust SM REIT and Suraksha Diagnostic concluded their IPOs in the first week of December. Vishal Mega Mart is looking to float an Rs 8,000 crore IPO, which will be entirely an offer-for-sale (OFS) of shares by promoter Kedaara Capital-led Samayat Services LLP, with no fresh issue of equity shares, according to the updated draft red herring prospectus (DRHP). The price band has been set at Rs 74 to Rs 78 per share. Sai Sai Life Sciences has fixed a price band of Rs 522 to Rs 549 per share for its Rs 3,043 crore initial public offering (IPO). This comprises a fresh issue of equity shares worth Rs 950 crore and an offer for sale (OFS) of 3.81 crore shares by a promoter, investor shareholders and other shareholders. The Mobikwik IPO is aiming to raise Rs 572 crore through a fresh issue of 2.05 crore shares. The price band for the offering has been set at Rs 265 to Rs 279 per share. The issue by Inventurus Knowledge Solutions consists entirely offer for sale, comprising 1.88 crore shares and merchant bankers have pegged the issue size at Rs 2,500 crore. International Gemmological Institute is eyeing Rs 4,225 crore through the IPO. The issue includes a fresh issue of equity shares worth Rs 1,475 crore and an OFS valued at Rs 2,750 crore by promoter BCP Asia II TopCo Pte Ltd, an affiliate of Blackstone, red herring prospectus showed. The share price band of Inventurus Knowledge Solutions and International Gemmological Institute will be announced on Monday. Upcoming SME IPOs are Dhanlaxmi Crop Science Ltd (December 9-11), Toss The Coin Ltd and Jungle Camps India Ltd (both December 10-12), Supreme Facility Management Ltd and Purple United Sales Ltd (December 11-13) and Yash Highvoltage Ltd (December 12-16). The primary market is experiencing strong interest from issuers and investors across various sectors. The IPO investors over the past five fiscal years have enjoyed significant gains. 236 IPOs launched between FY21 and FY25 delivered an average listing gain of 27 per cent for the retail bucket, with current gains soaring to 105 per cent (as of October 31, 2024), Trivesh stated. PTI Tags: BSE Business Investment IPO NSE Stock market Share Tweet Send Share Suggest A Correction Enter your email to get our daily news in your inbox. Leave this field empty if you're human:
Factbox-Trump likely to turn to tested trade law tools in his tariff offensive
None
Singapore—Meralco PowerGen Corp. (MGen), the power generation unit of Meralco., seeks to bolster its baseload portfolio by 1,280 megawatts (MW) with two coal plants awaiting the government’s green light. Coal plants are usually used as baseload, or the minimum power that needs to be injected into the grid at any given time, as they are the technology that can deliver the cheapest power around the clock. MGen’s baseload capacity is currently at 1,395 MW. READ: MGen’s Singapore unit vies for $900-M project In a chat with reporters, Emmanuel Rubio, president of MGen, said he learned the Department of Energy (DOE) was leaning toward giving them certificates of exception from the coal ban. The DOE had imposed a moratorium on new coal plants to control the country’s carbon emissions and support the government’s push to shift to clean energy. In July, the DOE clarified there was no total ban, which meant that existing and operational facilities that have made commitments for expansion may proceed. The group’s proposed coal-fired power plant project in Atimonan, Quezon province, Rubio previously said, was included in a list of projects that have already been “committed,” or projects that are in various stages of development. The project had also secured an environmental compliance certificate for the 1,200-MW project that claims to have low emissions. The Toledo facility, meanwhile, has original construction permits covering two units, with 80 MW each. Currently, it is running at an 82-MW capacity. Toledo Power Corp. is under Global Business Power, which is a wholly owned subsidiary of MGen. Rubio said the firm was already in talks with potential contractors and equipment suppliers for the planned Atimonan coal plant. “We have two candidates in Atimonan and so far we have one sure candidate for Toledo which was the original supplier, Formosa Heavy Industries,” he said late Tuesday. The official said MGen was likely to invest $1.6 million per MW. Once MGen secures the exception certificates, Rubio hopes to get the board’s go signal to proceed to the next stage, which would cover a feasibility study and engineering works. Subscribe to our daily newsletter By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy . Rubio also noted that banks—including four from the Philippines and two from Indonesia—already showed intent to back the projects.
Whales with a lot of money to spend have taken a noticeably bearish stance on Shopify . Looking at options history for Shopify SHOP we detected 18 trades. If we consider the specifics of each trade, it is accurate to state that 33% of the investors opened trades with bullish expectations and 44% with bearish. From the overall spotted trades, 2 are puts, for a total amount of $107,910 and 16, calls, for a total amount of $1,345,213. Expected Price Movements Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $40.0 to $115.0 for Shopify over the last 3 months. Volume & Open Interest Trends Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Shopify's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Shopify's significant trades, within a strike price range of $40.0 to $115.0, over the past month. Shopify Call and Put Volume: 30-Day Overview Biggest Options Spotted: Symbol PUT/CALL Trade Type Sentiment Exp. Date Ask Bid Price Strike Price Total Trade Price Open Interest Volume SHOP CALL TRADE NEUTRAL 06/20/25 $74.4 $72.15 $73.3 $40.00 $439.8K 342 65 SHOP CALL TRADE BULLISH 01/17/25 $5.2 $5.15 $5.2 $115.00 $260.0K 4.9K 514 SHOP CALL SWEEP BEARISH 12/06/24 $4.0 $3.8 $3.82 $110.00 $129.7K 2.5K 705 SHOP CALL SWEEP NEUTRAL 11/29/24 $3.7 $3.5 $3.59 $108.00 $83.9K 2.2K 1.0K SHOP PUT SWEEP BEARISH 12/27/24 $3.7 $3.5 $3.66 $110.00 $73.2K 349 202 About Shopify Shopify offers an e-commerce platform primarily to small and medium-size businesses. The firm has two segments. The subscription solutions segment allows Shopify merchants to conduct e-commerce on a variety of platforms, including the company's website, physical stores, pop-up stores, kiosks, social networks (Facebook), and Amazon. The merchant solutions segment offers add-on products for the platform that facilitate e-commerce and include Shopify Payments, Shopify Shipping, and Shopify Capital. Having examined the options trading patterns of Shopify, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance Current Position of Shopify With a volume of 2,565,336, the price of SHOP is down -0.68% at $111.32. RSI indicators hint that the underlying stock may be overbought. Next earnings are expected to be released in 76 days. Expert Opinions on Shopify 5 market experts have recently issued ratings for this stock, with a consensus target price of $113.4. Unusual Options Activity Detected: Smart Money on the Move Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. Click here for access .* Maintaining their stance, an analyst from Wells Fargo continues to hold a Overweight rating for Shopify, targeting a price of $120. * An analyst from Barclays persists with their Equal-Weight rating on Shopify, maintaining a target price of $93. * An analyst from Keybanc persists with their Overweight rating on Shopify, maintaining a target price of $130. * An analyst from Piper Sandler persists with their Neutral rating on Shopify, maintaining a target price of $94. * An analyst from Oppenheimer persists with their Outperform rating on Shopify, maintaining a target price of $130. Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely. If you want to stay updated on the latest options trades for Shopify, Benzinga Pro gives you real-time options trades alerts. © 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.No protester killed during LEAs operation against PTI sit-in: interior ministryA Farmingdale High School and Stony Brook University graduate is President-elect Donald Trump’s pick to oversee the Centers for Disease Control and Prevention, and if confirmed, he’d replace another Long Island native. The nomination of Dr. Dave Weldon, a former Republican congressman from Florida, has provoked concern from public health experts. He sponsored a bill to limit the use of vaccines containing mercury because of concerns the mercury-based preservative thimerosal could cause autism despite the CDC’s and leading health experts’ insistence that it does not, and sponsored a 2007 bill to strip the CDC of vaccine-safety responsibilities and move it to another agency within the Department of Health and Human Services. He would replace Dr. Mandy Cohen, a Baldwin native who in a statement released by the CDC after vaccine critic Robert F. Kennedy Jr.’s nomination for secretary of health and human services, but before Weldon’s, wrote: "I don't want to go backward and see children or adults suffer or lose their lives to remind us that vaccines work, and so I am concerned. Any misinformation coming from places of influence or power are concerning." K.C. Rondello, a clinical associate professor of public health at Adelphi University in Garden City, said in an email that he and others working in public health "are tremendously concerned about the potential impact of appointing a vaccine skeptic and conspiracy theorist to the role of CDC director. [Former] Rep. Weldon espouses beliefs that are contrary to the overwhelming mountain of evidence on vaccine efficacy and safety that has been garnered over decades." The CDC states that many studies have examined potential links between vaccines and autism and "continue to show that vaccines are not associated with ASD," or autism spectrum disorder. Children’s Health Defense, an organization that Kennedy founded, said in a statement: "We believe Dr. Weldon is eminently qualified as a former member of Congress and physician." The organization referred Newsday to an article on its website in which critics of the CDC praised Weldon for his criticism of the CDC’s vaccine safety oversight. Weldon was not available to comment, a Trump transition team spokeswoman said in an email. Weldon was born in Amityville, according to his official congressional biography , and graduated from Farmingdale High in 1971. He was among the first 16 Farmingdale alumni with their names inscribed on the school’s Wall of Honor, Newsday reported in 1998. He graduated from Stony Brook in 1978 with a bachelor of science in biochemistry, earning "high honors," university records show. He received his medical degree from the University at Buffalo in 1981. Weldon was a part-time clinical professor at the Florida Institute of Technology in Melbourne, Florida, from 2012 to 2019, and served on the university’s board of trustees from 2021 until January, the university said in an email. Weldon represented an east-central Florida congressional district from 1995 to 2009. His 2004 bill regarding thimerosal didn't pass. Thimerosal is added to vaccines to prevent germ growth and, according to the CDC , contains a type of mercury different than the one that is found in some fish. Studies have shown that low doses of thimerosal in vaccines are not harmful, other than minor reactions like redness at the injection site. Thimerosal was removed from childhood vaccines in 2001. It is in flu vaccines for adults and children, but there are thimerosal-free options. Weldon also has expressed concern about the safety of other vaccines, including those against measles, mumps and rubella, multiple news reports said. Dorit R. Reiss, a professor at University of California Law San Francisco and an expert on vaccine policy and law, said, "Weldon isn’t quite as extreme as Kennedy." But, she said, she is concerned that Weldon would push to no longer recommend certain vaccines and change CDC vaccine guidance. A committee of medical and public health experts, the Advisory Committee on Immunization Practices , advises the CDC on vaccines, but the CDC director can reject those recommendations, Reiss said. In addition, as health and human services secretary, Kennedy would have the power to appoint committee members. Recommendations are critical, because states generally follow them, she said. "Given the way this topic is politicized — which is a really sad thing, because viruses don't care about your politics — if the recommendations change suddenly, the reception would probably vary across states by political approach, and we may end up with a tragic national experiment in which some states stop recommending some vaccines and others don’t," Reiss said. In addition, the Affordable Care Act requires that most insurance plans pay for CDC-recommended vaccines if administered in-network. Many people won’t take vaccines if they must pay for them, Reiss said. "Some [insurance companies] will continue to cover vaccines that are not recommended because it's more cost effective for them to prevent disease than to treat it, but some won’t," she said. The CDC releases other advisories and recommendations. For example, the CDC website currently states that research shows that vaccines do not cause autism. If that changed, it could affect public trust in the CDC and put an official government stamp on baseless information, she said. A Farmingdale High School and Stony Brook University graduate is President-elect Donald Trump’s pick to oversee the Centers for Disease Control and Prevention, and if confirmed, he’d replace another Long Island native. The nomination of Dr. Dave Weldon, a former Republican congressman from Florida, has provoked concern from public health experts. He sponsored a bill to limit the use of vaccines containing mercury because of concerns the mercury-based preservative thimerosal could cause autism despite the CDC’s and leading health experts’ insistence that it does not, and sponsored a 2007 bill to strip the CDC of vaccine-safety responsibilities and move it to another agency within the Department of Health and Human Services. He would replace Dr. Mandy Cohen, a Baldwin native who in a statement released by the CDC after vaccine critic Robert F. Kennedy Jr.’s nomination for secretary of health and human services, but before Weldon’s, wrote: "I don't want to go backward and see children or adults suffer or lose their lives to remind us that vaccines work, and so I am concerned. Any misinformation coming from places of influence or power are concerning." K.C. Rondello, a clinical associate professor of public health at Adelphi University in Garden City, said in an email that he and others working in public health "are tremendously concerned about the potential impact of appointing a vaccine skeptic and conspiracy theorist to the role of CDC director. [Former] Rep. Weldon espouses beliefs that are contrary to the overwhelming mountain of evidence on vaccine efficacy and safety that has been garnered over decades." WHAT NEWSDAY FOUND The CDC states that many studies have examined potential links between vaccines and autism and "continue to show that vaccines are not associated with ASD," or autism spectrum disorder. Get the latest stories every week about health and wellness, covering topics from medicine and mental health to updates on the coronavirus and new research. By clicking Sign up, you agree to our privacy policy . Children’s Health Defense, an organization that Kennedy founded, said in a statement: "We believe Dr. Weldon is eminently qualified as a former member of Congress and physician." The organization referred Newsday to an article on its website in which critics of the CDC praised Weldon for his criticism of the CDC’s vaccine safety oversight. Weldon was not available to comment, a Trump transition team spokeswoman said in an email. Weldon was born in Amityville, according to his official congressional biography , and graduated from Farmingdale High in 1971. He was among the first 16 Farmingdale alumni with their names inscribed on the school’s Wall of Honor, Newsday reported in 1998. He graduated from Stony Brook in 1978 with a bachelor of science in biochemistry, earning "high honors," university records show. He received his medical degree from the University at Buffalo in 1981. Weldon was a part-time clinical professor at the Florida Institute of Technology in Melbourne, Florida, from 2012 to 2019, and served on the university’s board of trustees from 2021 until January, the university said in an email. Weldon represented an east-central Florida congressional district from 1995 to 2009. His 2004 bill regarding thimerosal didn't pass. Thimerosal is added to vaccines to prevent germ growth and, according to the CDC , contains a type of mercury different than the one that is found in some fish. Studies have shown that low doses of thimerosal in vaccines are not harmful, other than minor reactions like redness at the injection site. Thimerosal was removed from childhood vaccines in 2001. It is in flu vaccines for adults and children, but there are thimerosal-free options. Weldon also has expressed concern about the safety of other vaccines, including those against measles, mumps and rubella, multiple news reports said. Dorit R. Reiss, a professor at University of California Law San Francisco and an expert on vaccine policy and law, said, "Weldon isn’t quite as extreme as Kennedy." But, she said, she is concerned that Weldon would push to no longer recommend certain vaccines and change CDC vaccine guidance. A committee of medical and public health experts, the Advisory Committee on Immunization Practices , advises the CDC on vaccines, but the CDC director can reject those recommendations, Reiss said. In addition, as health and human services secretary, Kennedy would have the power to appoint committee members. Recommendations are critical, because states generally follow them, she said. "Given the way this topic is politicized — which is a really sad thing, because viruses don't care about your politics — if the recommendations change suddenly, the reception would probably vary across states by political approach, and we may end up with a tragic national experiment in which some states stop recommending some vaccines and others don’t," Reiss said. In addition, the Affordable Care Act requires that most insurance plans pay for CDC-recommended vaccines if administered in-network. Many people won’t take vaccines if they must pay for them, Reiss said. "Some [insurance companies] will continue to cover vaccines that are not recommended because it's more cost effective for them to prevent disease than to treat it, but some won’t," she said. The CDC releases other advisories and recommendations. For example, the CDC website currently states that research shows that vaccines do not cause autism. If that changed, it could affect public trust in the CDC and put an official government stamp on baseless information, she said. David Olson covers health care. He has worked at Newsday since 2015 and previously covered immigration, multicultural issues and religion at The Press-Enterprise in Southern California.